A higher percentage of MMR-proficient tumors with BRAF ( V@E ) were proximal ( @ % ) , high-grade ( @ % ) , N@ stage ( @ % ) , and detected in women ( @ % ) , compared with MMR-proficient tumors without BRAF ( V@E ) or KRAS mutations ( @ % , @ % , @ % , and @ % , respectively ; all P < @ ) .